Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Diseases

What this Trial Is About

Researchers are studying genetic factors and molecular pathways involved in various genitourinary cancers, including kidney, prostate, bladder, testis, and penile cancers. These cancers represent a significant portion of cancer diagnoses and deaths in the United States. The study aims to understand the differences between normal and cancerous tissues, investigate gene and protein markers, and examine responses to current and new treatments. The research also includes quality of life studies in men with prostate cancer and explores inherited conditions linked to increased cancer risk. Participants include individuals with biopsy-proven or suspected malignant genitourinary diseases, those with known or suspected inherited cancer disorders, and family members related by blood to affected individuals. Blood and urine samples may be collected, and tissue samples—both benign and malignant—may be obtained during clinically necessary surgeries. The study involves genetic sequencing and molecular analysis of collected specimens, with ongoing investigations into gene mutations and biochemical pathways. During participation, patients will be seen at the Urologic Oncology Branch, where samples will be collected and stored for research. Participants may be contacted if findings relevant to their health arise, with the opportunity for further evaluation. The study involves ongoing assessments of quality of life and molecular genetic outcomes. Participation includes signing informed consent, and the study accommodates both adult and pediatric patients, tracking molecular and clinical data over time.

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease